Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies

Author(s): Joesph Mikhael and Hong Chang

Volume 4, Issue 2, 2007

Page: [82 - 86] Pages: 5

DOI: 10.2174/157018007779422541

Price: $65

Abstract

The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.

Keywords: Proteasome inhibitor, Bortezomib, Multiple myeloma, Clinical trial, Cancer


© 2024 Bentham Science Publishers | Privacy Policy